The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- PNV
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-51
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.34 |
Change
-0.040(1.68%) |
Mkt cap ! $1.615B |
Open | High | Low | Value | Volume |
$2.43 | $2.43 | $2.33 | $1.728M | 733.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4407 | $2.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.34 | 16721 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2602 | 2.330 |
8 | 15948 | 2.320 |
5 | 19030 | 2.310 |
9 | 23525 | 2.300 |
5 | 13953 | 2.290 |
Price($) | Vol. | No. |
---|---|---|
2.340 | 16721 | 2 |
2.350 | 9130 | 4 |
2.360 | 7740 | 2 |
2.370 | 7740 | 2 |
2.380 | 2602 | 1 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |